| Date Filed | Type | Description |
| 08/10/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/09/2023 |
8-K
| Quarterly results |
| 08/01/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/19/2023 |
4
| Zaknoen Sara (Director) has filed a Form 4 on aTYR PHARMA INC|
Txns:
| Granted 12,000 options to buy
@ $2.52, valued at
$30.2k
|
|
| 05/19/2023 |
4
| SCHIMMEL PAUL (Director) has filed a Form 4 on aTYR PHARMA INC|
Txns:
| Granted 12,000 options to buy
@ $2.52, valued at
$30.2k
|
|
| 05/19/2023 |
4
| Lucas Svetlana (Director) has filed a Form 4 on aTYR PHARMA INC|
Txns:
| Granted 12,000 options to buy
@ $2.52, valued at
$30.2k
|
|
| 05/19/2023 |
4
| Gross Jane A (Director) has filed a Form 4 on aTYR PHARMA INC|
Txns:
| Granted 12,000 options to buy
@ $2.52, valued at
$30.2k
|
|
| 05/19/2023 |
4
| COUGHLIN TIMOTHY (Director) has filed a Form 4 on aTYR PHARMA INC|
Txns:
| Gifted 6,000 shares
@ $0
Gifted 6,000 shares
@ $0
Granted 12,000 options to buy
@ $2.52, valued at
$30.2k
|
|
| 05/19/2023 |
4
| CLARKE JOHN K (Director) has filed a Form 4 on aTYR PHARMA INC|
Txns:
| Granted 12,000 options to buy
@ $2.52, valued at
$30.2k
|
|
| 05/19/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"CERTIFICATE OF AMENDMENT TO THE RESTATED CERTIFICATE OF INCORPORATIONOF",
"ATYR PHARMA, INC. 2015 STOCK OPTION AND INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the aTyr Pharma, Inc. 2015 Stock Option and Incentive Plan . The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of aTyr Pharma, Inc., a Delaware corporation , and its Subsidiaries upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company’s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company’s behalf and stre...",
"Code of Business Conduct and Ethics Introduction Purpose and Scope The Board of Directors of aTyr Pharma, Inc. established this Code of Business Conduct and Ethics to aid the Company’s directors, officers and employees in making ethical and legal decisions when conducting the Company’s business and performing their day-to-day duties. The Company’s Board of Directors or a committee of the Board is responsible for administering the Code. The Board has delegated day-to-day responsibility for administering and interpreting the Code to a Compliance Officer. Our General Counsel has been appointed the Company’s Compliance Officer under this Code. The Company expects its directors, officers and employees to exercise reasonable judgment when conducting the Company’s business. The Company encourages..." |
|
| 05/11/2023 |
4
| SCHIMMEL PAUL (Director) has filed a Form 4 on aTYR PHARMA INC|
Txns:
| Bought 200,000 shares
@ $2.25, valued at
$450k
|
|
| 05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/09/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/28/2023 |
4
| CLARKE JOHN K (Director) has filed a Form 4 on aTYR PHARMA INC|
Txns:
| Exercised 6,000 restricted stock units
@ $0 |
|
| 04/28/2023 |
4
| SCHIMMEL PAUL (Director) has filed a Form 4 on aTYR PHARMA INC|
Txns:
| Exercised 6,000 restricted stock units
@ $0 |
|
| 04/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/28/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/18/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 03/29/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/29/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 03/29/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/14/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/10/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 03/09/2023 |
8-K
| Quarterly results |
| 02/22/2023 |
SC 13G
| LYTTON LAURENCE W reports a 8.7% stake in aTyr Pharma, Inc. |
| 02/21/2023 |
4
| Shukla Sanjay (President and CEO) has filed a Form 4 on aTYR PHARMA INC|
Txns:
| Granted 336,096 options to buy
@ $2.195, valued at
$737.7k
|
|
| 02/21/2023 |
4
| Broadfoot Jill Marie (CFO) has filed a Form 4 on aTYR PHARMA INC|
Txns:
| Granted 84,023 options to buy
@ $2.195, valued at
$184.4k
|
|
| 02/21/2023 |
4
| DENYES NANCY (General Counsel) has filed a Form 4 on aTYR PHARMA INC|
Txns:
| Granted 84,023 options to buy
@ $2.195, valued at
$184.4k
|
|
| 02/14/2023 |
SC 13G/A
| Venrock Healthcare Capital Partners II, L.P. reports a 4% stake in aTyr Pharma, Inc. |
| 02/09/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"22,225,000 Shares ATYR PHARMA, INC. Common Stock UNDERWRITING AGREEMENT February 8, 2023 RBC CAPITAL MARKETS, LLC As Representative of the several Underwriters named in Schedule I hereto c/o RBC Capital Markets, LLC Brookfield Place 200 Vesey Street, 8th Floor New York, New York 10281",
"3545 John Hopkins Court, Suite" |
|
| 02/09/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
|